Investigação de novos biomarcadores de lesão renal em pacientes com lúpus eritematoso sistêmico atendidos em hospital universitário de Fortaleza-Ceará

• Ano de defesa: 2021
• Autor(a) principal: Castro, Valeska Queiroz de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Lúpus Eritematoso Sistêmico; Biomarcadores; Injúria Renal Aguda
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/59469

Systemic lupus erythematosus (SLE) is an autoimmune disease that can lead to the involvement of multiple organs, including the kidneys. Early diagnosis of kidney injury can prevent health problems in addition to providing better clinical management. The present study aimed to evaluate new biomarkers and biomarkers already known for kidney injury in patients with SLE in order to predict kidney dysfunction early in these patients. Methods: A cross-sectional study was carried out, from August 2018 to July 2020, at the rheumatology outpatient clinic of the University Hospital Walter Cantídio, in Fortaleza-CE. Blood and urine samples were collected from patients diagnosed with SLE, as well as the application of a specific sociodemographic questionnaire. Patients diagnosed with SLE older than 18 years of both sexes and without previous kidney disease were included. Renal function was assessed using serum creatinine, urea and estimated glomerular filtration rate (eGFR). Urinary nephrin and vascular biomarkers VCAM-1, angiotensin-2 and syndecan-1 were quantified by ELISA. Results: Regarding the VCAM-1 and Syndecan-1 biomarkers, patients with detectable nephrin had a higher mean value (1,151.58; p = 0.002 and 87.5; p > 0.001, respectively). The other laboratory parameters evaluated showed normal values, including the results of urea and creatinine, considered as traditional markers of kidney injury. Conclusion: There was no association between nephrinuria and proteinuria, GFR and serum creatinine in SLE patients without lupus nephritis. However, the study showed an association between nephrinuria and the biomarkers VCAM-1 and syndecan-1, which are vascular biomarkers involved in endothelial dysfunction. The use of new biomarkers of early kidney injury in clinical practice, in association with other parameters involved in the pathophysiology and prognosis of SLE, can facilitate the development of more effective strategies for the treatment and monitoring of SLE-associated nephropathies, as well as contributing to the prevention of injuries to the patients' clinical condition.